OSI Tarceva Approval Falls Flat: Wall Street Wants Aggressive Pricing
OSI's early experience with the launch of Tarceva suggests that managing investor expectations for a new-model breakthrough medicine may be as challenging as demonstrating a survival benefit in lung cancer
You may also be interested in...
Biogen Idec/Elan's once-monthly I.V. formulation of the multiple sclerosis therapy Tysabri guarantees that the product will be covered under Medicare Part B
Genentech/OSI will price the EGFR inhibitor Tarceva between AstraZeneca's Iressa and Novartis' Gleevec, OSI CEO Colin Goddard, PhD, said
The prices set by Genentech and Bristol-Myers Squibb for their recently launched colorectal cancer therapies are an invitation to impose price controls, former Memorial-Sloan Kettering Cancer Center Physician-in-Chief Robert Wittes, MD, wrote in an editorial published by the Washington Post June 15